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The recently updated Durie/Salmon PLUS staging system published in 2006 highlights the many advances that have been made
in the imaging of multiple myeloma, a common malignancy of plasma cells. In this article, we shall focus primarily on the
more sensitive and speciﬁc whole-body imaging techniques, including whole-body computed tomography, whole-body magnetic
resonance imaging, and positron emission computed tomography. We shall also discuss new and emerging imaging techniques
and future developments in the radiological assessment of multiple myeloma.
1.Introduction
Multiple myeloma is a neoplastic disorder of plasma B
cells characterised by bone marrow inﬁltration and overpro-
duction of monoclonal immunoglobulins. It accounts for
approximately 10% of all haematological malignancies and
1% of all cancers with an increasing incidence, aﬀecting
four in every 100,000 per year [1]. It predominantly aﬀects
patients in the seventh decade and has high morbidity and
mortality. Patient survival has improved over the past decade
with the introduction of novel chemotherapeutic agents [2,
3].
Standard investigations for multiple myeloma includes
a complete blood count, serum biochemistry, serum and
urine electrophoresis, and the gold standard for diagnosis:
bone marrow aspirate and biopsy. The Durie/Salmon staging
system introduced in 1975 used skeletal survey as its only
radiological criterion [4]. In an eﬀort to standardize treat-
ment approaches and stage the disease as accurately as possi-
ble at the time of diagnosis, the Durie/Salmon PLUS staging
system has been introduced, integrating the more sensitive
imaging techniques of magnetic resonance imaging (MRI),
computed tomography (CT), and PET/CT information into
its classiﬁcation system [5].
The role of radiological imaging in multiple myeloma is
essentially three fold: in the initial staging of the disease, in
the detection and characterisation of complications, and in
the evaluation of patient’s response to treatment.
2. The Biology of Myeloma Bone Disease
In the past decade, the role of the bone marrow microen-
vironment has been at the forefront of multiple myeloma
research. The “seed and soil” hypothesis was ﬁrst introduced
in the late 1800s by an English surgeon, Dr. Stephen Paget,
who proposed a neoplastic growth (the seed, e.g., the
myeloma cell) will proliferate in an environment (the soil,
e.g., bone marrow environment) that supports its’ replica-
tion [6]. Since then, in particular in the early 21st century, a
multitude of evidence has emerged demonstrating the role
of the myeloma cells local environment in augmenting its
survival.
The bony destructive lesions demonstrated by myeloma
imaging techniques are caused by myeloma cell-mediated
promotion of osteoclast-mediated bony destruction and
inhibition of osteoblast-mediated bone anabolism. Myeloma
cells attach to osteoclasts directly by numerous adhe-
sion molecules, one example being vascular cell adhesion2 Bone Marrow Research
Figure 1: Lateral radiograph skull: diﬀuse lytic lesions giving
classical “pepper pot skull” appearance.
molecule-1 (VCAM-1), with resultant stimulation of osteo-
clastogenesis [7].
The eﬀects of myeloma cells on attenuation of osteoblas-
tic activity can be explained, for the most part, by inhibition
of osteoblastic diﬀerentiation into mature osteoblasts. The
main pathway involved in inhibition of osteoblastogenesis
is by direct cell-to-cell contact between the mesenchymal
stem cells (MSCs) and the myeloma cells. Adhesion of these
two entities via VCAM-1 and very late antigen-4 (VLA-4)
results in a reduction in Runt-related transcription factor 2
(RUNX2) expression, a critical factor involved in osteoblast
transcription [8]. Secondly, myeloma cells secrete factors
that inhibit diﬀerentiation of osteoblasts, such as Dickkopf
1 (DKK-1), tumour necrosis factor alpha (TNF-α), soluble
frizzled-related protein-2 (SFRP-2), and Activin A. DKK-1
and SFRP-2 act by inhibiting the Wnt pathway, a pathway
that plays a signiﬁcant role in osteoblastic maturation [9].
3.ImagingTechniques
3.1. Plain Radiography. Af u l ls k e l e t a ls u r v e yi n c l u d e sa
frontal and lateral view of the skull, the cervical, thoracic and
lumbar spine, a coned-down frontal view of the dens axis, as
well as frontal views of the rib cage, humeri, femora, knees,
and pelvis. There is a clear association between the extent of
disease, in terms of number of lytic lesions at presentation,
and tumour load at diagnosis [4]. Almost 80% of patients
with multiple myeloma will have radiological evidence of
skeletal involvement on the skeletal survey most commonly
eﬀecting the following sites: vertebrae in 66%, ribs in 45%,
skull in 40%, shoulder in 40%, pelvis in 30%, and long
bones in 25% (Figures 1 and 2)[ 10]. Plain radiography has
the advantage over MRI in detecting cortical bone lesions.
It also has the advantage of being universally available, and
relatively inexpensive.
One of the major disadvantages of plain radiography is
its high false-negative rate of 30–70%, leading to signiﬁcant
underestimation in diagnosis and staging of patients with
multiple myeloma [11–13]. Diﬀuse bone marrow involve-
ment,whichmayormaynotbeassociatedwithcorticalbone
destruction,isnotevaluableusingconventionalradiography.
Lytic lesions become apparent on conventional radiography
when 30–50% of the bone mineral density is already lost [14,
R
Figure 2: A-P radiograph right humerus: diﬀuse lytic lesions of
the right humerus (arrowed) with old pathological fracture distal
diaphysis (arrow).
Figure 3: Axial CT pelvis: diﬀuse myeloma involving the sacrum
and iliac bones bilaterally, with cortical destruction of the left iliac
bone (arrow).
15]. Furthermore, diﬀuse osteopenia as a result of multiple
myeloma cannot be distinguished on plain radiographs from
more common causes of osteopenia, such as senile and
postmenopausal osteoporosis [13]. A practical drawback
of plain radiography is that varied positions required for
radiography ﬁlms are painful for patients who are often
elderly and disabled due to previous pathological fractures.
3.2. Computed Tomography (CT). CT is a sensitive imaging
modality in detecting the osteolytic eﬀects of multiple
myeloma and has a higher sensitivity than plain radiography
at detecting small lytic lesions [16]. CT ﬁndings in multiple
myeloma consist of punched-out lytic lesions, expansile
lesions with soft tissue masses, diﬀuse osteopenia, fractures,
and, rarely, osteosclerosis (Figures 3 and 4)[ 16]. Mahnken et
al. compared multidetector row CT with conventional radio-
graphy and MR imaging in patients with newly diagnosedBone Marrow Research 3
S
I
Figure 4: Volume rendering 3-dimensional reconstruction of
lumbar spine and pelvis: multiple “punched-out” lytic lesions
throughout lumbar spine and pelvis (arrow).
multiple myeloma [16]. Multi-detector CT was superior to
conventional radiography at deﬁning lytic lesions and, in
combinationwithMRimaging, aidedinstaging theextent of
the disease. CT allowed a more accurate evaluation of areas
at risk of fracture than did MR imaging. CT is of use in iden-
tifying bone destruction in cases where MR is negative, and
hencemayprovidecomplementaryimaginginformation.CT
has the advantage of accurately demonstrating the presence
and extent of extraosseous lesions and is the tool of choice
utilised in image guided spinal or pelvic bone biopsy of MR
imaging deﬁned focal lesions [17].
Traditionally, whole-body CT has not been used for
screening purposes due to the high level of radiation
exposure. Low-dose CT techniques are being developed as a
possiblealternativetoplainradiography(Figure 5)[18].Due
to the high intrinsic contrast of bone, the tube current can
be lowered signiﬁcantly (i.e., to 50–100mAs, depending on
the weight of the patient), resulting in an eﬀective equivalent
dose in the same range as that of a skeletal survey (4–5mSv).
CT also has the practical advantage of being quick, with
the patient lying comfortable on his or her back. Iodine-
containing contrast agents, which are contraindicated in
patients with multiple myeloma due to the risk of cast
nephropathy and renal impairment, are not required for
skeletal CT making it an even more attractive screening
option. A drawback of CT is that it typically shows persistent
bone lesions throughout the course of the disease and, unlike
S
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(b)
Figure 5: Low dose sagittal whole-body CT (a): note lytic lesion
posterior aspect of T10 vertebral body (arrow). Background of
extensive osseous permeation from myeloma. Axial CT thorax in
the same patient at the level of T10 (b) identifying lytic inﬁltration
of vertebral body (arrow).
MRI and PET/CT, it cannot assess continued activity of
myeloma in areas of prior bone destruction [5].
3.3. Whole-Body MRI. Whole-body MR (WBMR) has
emerged as the most sensitive imaging modality to date at
detecting diﬀuse and focal multiple myeloma in the spine,
as well as the extra-axial skeleton [19–21]. Due to its ability
to visualise large volumes of bone marrow without inducing
radiation exposure and in an acceptable amount of time, MR
imaging has become a favoured imaging method for evaluat-
ing disease within the bone marrow (Figure 6). MR also has
prognostic signiﬁcance; the number and pattern of lesions
detectedonMRIcorrelatesverywellwithtreatmentoutcome
and overall survival [5, 20]. The excellent correlation with
survivaloutcomesistheprimary reasonforinclusion ofMRI
into the Durie/Salmon PLUS system [5]. It is important to
note that MRI predominately reﬂects marrow inﬁltration,
which may or may not be associated with bone destruction.
T h et y p eo fM Rs e q u e n c ea p p l i e dg r e a t l ya ﬀects the
MR images. Multiple sequences have been proposed for
use in identifying focal or diﬀuse disease of the bone mar-
row. These include spin-echo (T1-weighted and T2-weight-
ed), gradient-echo (T2∗-weighted), STIR (short time inver-
sion recovery), and contrast-enhanced spin-echo (with and
without fat suppression) sequences [22]. The term “dynamic
contrast-enhanced MRI” denotes repeat scanning with high
temporal resolution before, during, and after intravenous
infusion of a gadolinium-containing contrast agent, using4 Bone Marrow Research
Figure 6: Whole-body MRI coronal and selective axial STIR sequence. Left image: coronal STIR sequence demonstrating T2 bright
myelomatous disease throughout the thoracic spine (rectangle). Centre image: coronal T1-weighted sequence demonstrating low signal
marrow throughout the lumbar spine due the myelomatous inﬁltration (rectangle). Right image: 3 axial MRI images at the level of the vocal
cords, lumbar spine, and ischium, T1-weighted sequence following administration of contrast.
(a) (b)
Figure 7: (a) MRI sagittal T1-weighted sequence lumbar spine: dif-
fuse permeative low signal myelomatous marrow lesions through-
out the lumbar spine (arrow). (b) MRI sagittal T2-weighted STIR
sequence (same patient): diﬀuse high signal myelomatous marrow
lesions throughout the lumbar spine (arrow).
fast T1-weighted sequences [23]. The change in signal inten-
sity over time in a given region is a function of local perfu-
sion, relative blood volume, capillary surface exchange area,
vessel permeability, and systemic elimination. Diﬀusion-
weighted imaging (DWI) is increasingly being studied on
patients with multiple myeloma [23]. DWI analyses the
freedom of movement of interstitial water molecules, which
depends on many factors, such as cell density or the presence
of organised structures (e.g., ﬁbres). Studies have shown that
diﬀusion is impaired within tumours, and that a decrease
in diﬀusion may indicate disease progression. Eﬀective
treatment may cause a transient decrease in diﬀusion, owing
to toxic cell swelling, but thereafter, as the cellular load is
reduced, diﬀusion increases signiﬁcantly.
Typical myeloma lesions are marrow based and have
low signal intensity on T1-weighted images (Figure 7(a)),
and a high signal intensity on T2-weighted sequences and
STIR images (Figure 7(b)) and generally show enhancement
on gadolinium-enhanced images. Four patterns of mar-
row involvement have been identiﬁed. A normal marrow
appearance is present at diagnosis in 50–70% of untreated
Durie/Salmonstage1andin20%ofuntreatedDurie/Salmon
stage 3 [23]. Other marrow appearances of untreated disease
include a focal pattern, a diﬀuse pattern and a variegated
appearance. Thus the main drawback of MR imaging is the
lack of speciﬁcity. Focal or diﬀu s ep a t t e r n sm a ye x i s ta t
diagnosis and may be a variation of the norm, or reﬂect an
alternative pathological or physiological process.
Whole-body STIR imaging has gained wider acceptance
in detecting occult malignant disease in the skeleton [24, 25].
With ongoing technical advances, such as the moving table,
use of multicoil elements, and advances in image processing
technology, this technique is becoming more feasible and
quicker to perform. Increasing the number of sequences will
improvespeciﬁcityofimages,thedownsidebeinganincrease
inacquisitiontime.Thesenewertechniquesenabletheinclu-
sion of such sites as the sternum, skull, and ribs, which are
usually excluded from standard MR imaging protocols in
multiple myeloma.Bone Marrow Research 5
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Figure 8: A-P radiograph right knee (a): 4cm lucency medial
femoralcondyle(arrow),radiographicallydiﬃculttovisualise.MRI
coronal T2-weighted STIR sequence (b, same patient): high signal
4cm plasmacytoma medial femoral condyle (arrow).
Dedicated focal MR imaging of the skull, spine, pelvis,
or of an extremity is also still a widely utilized technique.
MR imaging is routinely required to evaluate the extent and
characteristics of a solitary lytic lesion identiﬁed at plain
radiography (Figure 8) .T h e r ei so f t e naw i d ed i ﬀerential for
such a lesion, from benign lesions such as osteomyelitis and
ﬁbrous dysplasia to malignant processes such as metastases
and myeloma.
3.4. Nuclear Medicine Imaging (Bone Scintigraphy, PET/CT,
and MIBI Scanning)
3.4.1. Bone Scintigraphy. Bone scintigraphy is of limited
use in multiple myeloma. Detection of bone involvement
using technetium 99-m (99mTc) labelled diphosphonates
relies on the osteoblastic response and activity of the skeletal
system for uptake. Multiple myeloma, however, is primarily
an osteolytic neoplasm. Lesions that are well deﬁned on
isotopebonescansaretheresultofcomplicationsofmultiple
myeloma, namely, osteoblastic response to a compression
fracture of a vertebral body or pelvic insuﬃciency fracture.
Bonescintigraphymaybehelpfulinevaluatingareasnotwell
demonstrated in plain radiography, such as ribs and sternum
[26]. In a report comparing the skeletal survey with isotope
bone scans, uptake of the radioisotope in radiographically
abnormal regions occurred in 44% of cases, normal ﬁndings
were seen in 48%, and diminished uptake was seen in 8%
[27].
3.4.2. PET/CT. Positron emission computed, tomography
(PET/CT) is a tomographic nuclear imaging technique
that uses a labelled radiopharmaceutical such as 18ﬂouro-
deoxy-glucose (FDG) injected into the patient, followed by
tomographic scanning approximately 10–40 minutes later.
Tumour cells can be imaged with this technique due to their
high metabolic rate and the resulting high glucose demand,
allowing tumour cells to be distinguished from normal cells.
Figure 9: Axial fused PET/CT thorax at the level of the pulmonary
bifurcation: massive right-sided chest wall plasmacytoma (arrow).
Currently, PET/CT is being evaluated in patients with multi-
plem y elo maandma yd et ectearl ybo nemarr o win v ol v e me nt
in patients with apparently solitary plasmacytoma [28], to
assess the extent of active disease, detect extramedullary
involvement or evaluate treatment response [29].
The main limitation of PET imaging (without the CT
component) is limited spatial resolution, which may result
inlimitationsindetectingsubcentimetrelyticlesionsseenon
plain radiography. The advent of fusion scanning combining
both the PET component and CT component addresses this
issue. In PET/CT fusion scanning, the patient receives an
injection of FDG about 1 hour before image acquisition. An
initial topogram is acquired to deﬁne the range of image
acquisition. A spiral CT is then performed. The actual scan-
ning time is shorter for PET/CT (approximately 30 minutes)
than for a PET scan alone (approximately 1 hour) as CT data
is used to perform attenuation correction (Figure 9).
One of the most signiﬁcant advantages of PET/CT imag-
ing is its ability to distinguish between active myeloma (FDG
positive)andmonoclonalgammopathyofundeterminedsig-
niﬁcance (MGUS) or smouldering disease. MGUS is usually
negative on PET/CT with neither diﬀuse marrow uptake
nor focal disease in marrow sites [13]. Active myeloma is
FDG positive for focal and diﬀuse abnormities and FDG
uptake decreases rapidly after eﬀective therapy. Persistent
FDG positivity correlates with early relapse as is discussed
later.Thisrapidresponsetotreatmentisconversetothatseen
with MRI where there may be a time lag of 9–12 months in
the reversal of MRI abnormalities despite successful therapy
[20].
How does PET/CT compare with other imaging modal-
ities? In a series of 43 patients with multiple myeloma and
solitary plasmacytoma,Shirrmeister et al.[28]r e po rt edf oc a l
traceruptakeonPET/CTscansof38of41lesions(sensitivity,
93%) with known osteolytic pattern. PET/CT depicted 71
additionallesionsmissedonplainradiographyin14patients,
which resulted in a change in disease management in 14%
of patients studied. Few studies exist directly comparing
PET/CT with MRI. A recent study by Shortt et al. [30]
compared PET/CT with whole-body MRI in patients with
bone biopsy proven multiple myeloma. Whole-body MRI
performed better than PET/CT in assessing disease activity
having a higher sensitivity (68% versus 59%) and speciﬁcity
(83%versus75%)thanPET/CT.Whenusedincombination,6 Bone Marrow Research
Figure 10: Axial CT thorax postintravenous contrast at the level
of T6: diﬀuse bilateral hilar lymphadenopathy from biopsy-proven
multiple myeloma (arrows).
PET/CT and whole-body MRI were found to have a positive
predictive value of 100%.
False-positive PET/CT scans may arise from inﬂamma-
tory changes due to active infection, chemotherapy within
the preceding 4 weeks, or radiation therapy within the
preceding 2-3 months [31].
3.4.3. MIBI Scanning. 99Technitium sestamibi (MIBI) imag-
ing is an alternative nuclear imaging modality that uses
Tc-99m-2-methoxy-isobutyl-isonitrile as a tumour-seeking
tracer to identify areas of active disease in a variety of
tumours including plasma cell dyscrasias. Using MIBI imag-
ing, it is possible to scan both skeletal lesions and soft
tissue lesions and the overall sensitivity is approximately
92% and speciﬁcity is 96% [32]. 99Tc-MIBI is superior
when compared with PET/CT for the visualisation of diﬀuse
disease and despite its limited capacity in detecting focal
lesions, this technique may be an alternative option when
PET/CT is not available. In comparison to MRI, it has been
shown that 99Tc-MIBI underestimates the extent of bone
marrow inﬁltration in the spine, especially in patients with
low disease stage [33]. 99Tc-MIBI may be useful in the
detection of indolent disease, as very low-level myeloma is
not detectable on PET/CT [5, 34]. An important nuance of
99Tc-MIBI scanning is the enhanced uptake of 99Tc-MIBI by
drug-resistantmyelomacellsversusenhanceduptakeofFDG
by metabolically active myeloma cells [34].
4.ImagingofExtramedullary
MultipleMyeloma
Extramedullary multiple myeloma is uncommon. In one
review of 432 patients with multiple myeloma, only 19
(4.4%) were identiﬁed as having extramedullary multiple
myeloma [35]. Multiple myeloma often produces gross ster-
nal expansion and distortion and vertebral body destruction.
The pathological tissue appears as soft tissue attenuation
similar to muscle at CT, with a degree of enhancement after
contrast. MRI typically reveals masses of uniform low signal
on T1-weighted image, and uniform high signal on T2-
weighted image. Later in the disease cortical breaches may
occur, and further local spread from bone may be seen,
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Figure 11: Axial fused PET/CT at the level of T2 vertebra: extensive
FDG-avid biopsy-proven amyloid left deltoid muscle in a patient
with multiple myeloma (arrow).
producing masses in the surrounding soft tissues (Figures 9,
10,a n d11). CT is superior to MRI in depicting early cortical
breaches [36].
5. Imagingof Response to Treatment
andDisease Progression
The choice of imaging modality for assessing response
to treatment or disease progression generally depends on
the ﬁndings from the initial workup and the patients’
speciﬁc treatment regime. Although new or enlarging lesions
generally signify disease progression, lytic bone lesions rarely
show evidence of healing on plain radiographs, and routine
follow-up skeletal survey is of questionable beneﬁt and not
routinely indicated in monitoring disease progression or
response to treatment. New vertebral compression fractures
on plain radiography do not always signify disease progres-
sion and may occur even after eﬀective treatment, due to the
resolution of the tumour mass that was supporting the bony
cortex [37].
CT in the followup of treated disease may demonstrate
the resolution of extramedullary disease, and the reappear-
ance of a continuous cortical outline. Fatty marrow content
may be seen in treated lytic disease in treated cases [38]. As
mentioned earlier, one of the nuances of CT is that it cannot
assess continued activity of myeloma in areas of prior bone
destruction.
Although very accurate, MRI is not ideal for serial moni-
toring, as it takes 9–12 months for lesions evident on MRI to
resolve and be clearly indicative of response [20]. There are a
wide spectrum of treatment-induced changes seen on MRI
following treatment. MR imaging may fail to demonstrate
evidenceofregressionofmyelomainﬁltrationinthemarrow.
Focal lesions may shrink or remain unchanged in size.
A complete response to treatment may be evidenced by
complete resolution of the preceding marrow abnormality,
and a partial response demonstrated by conversion of a
diﬀuse to a variegated or focal pattern [22]. A good response
to treatment may also be evidenced by a reduction in signal
intensity on T2-weighted spin echo images and the absence
of contrast-induced rim enhancement that was previously
present [19].
Diﬀuse or focal marrow changes may occur following
treatment with synthetic growth factors including GCSF and
erythropoietin that may simulate active disease on MR orBone Marrow Research 7
PET/CTimaging[2].ArtiﬁcialalterationsofFDGactivityare
typically limited to a 1-month interval after discontinuation
of treatment [39].
PET/CT imaging has been shown to be useful in evalu-
ating response to therapy, particularly when other imaging
techniques, such as MRI or CT have remained abnormal or
inconclusive. PET/CT may identify new sites of disease as
well as unsuspected extramedullary spread. Patients appear
to have a particularly poor prognosis if abnormal FDG
uptake is present following high-dose therapy or stem cell
transplantation[40].InarecentstudybyBarteletal.in2009,
it was demonstrated that several imaging parameters related
to tumour burden, such as focal lesion number assessed by
MRI, and intensity of tumour metabolism on PET/CT, aﬀect
survival outcomes [41]. 239 patients with newly diagnosed,
untreated symptomatic multiple myeloma enlisted in the
Total Therapy 3 program and were evaluated using plain
radiographic survey, MRI and PET/CT. Complete FDG
suppression in focal lesions and metastatic spread before
transplantation conferred superior overall and event-free
survival. At 30 months from ﬁrst autotransplantation, 92%
and 89%, respectively, were alive and event-free compared
with 71% and 63% among those with less than 100%
suppression of FDG uptake in focal lesions or metastatic
spread. The presence of more than 3 FDG-avid focal lesions
was the leading independent parameter associated with an
inferior overall and event-free survival. The prognosis of
high-risk patients in this study not achieving complete FDG
suppression was poor, which supports the use of serial
PET/CT examinations in high-risk patients to individu-
alise therapy and prompt changes to alternative therapies.
Importantly, persistent FDG positivity can occur when bone
marrow and M-component markers are negative [5].
Despite the plethora of reports on the use of MIBI in
the assessment of myeloma patients, the main limiting factor
remains its limited sensitivity and speciﬁcity, the relatively
low numbers of patients included in the reports, and the
heterogeneity of clinical situations described [42].
6. New Developments
In the late 1990s in the USA, triggered by faster image
acquisition, several groups of researchers revisited the earlier
work of Dermadian’s and Lauturbur’s described techniques
allowing rapid whole-body imaging using MR imaging. A
relativelynewwholebodycoilsystemisnowavailablewith76
coil elements and 32 high-frequency channels on a 1.5-tesla
system. This new system allows for coronal STIR imaging
with a ﬁeld-of-view of 205 cm within 14 minutes with high
spatial resolution.
The ﬁrst whole-body MR study was performed by
Eustace et al. in 1997 [43]. Whole-body MR is now feasible
in routine clinical practice. Diﬀusion weighted imaging of
non-CNS tissue has attracted much attention during the
past decade. Most experience to date has been gained in
diﬀerentiating benign from pathological vertebral compres-
sion fractures, which can be reliably done when quantitative
diﬀusion measurements are available. Preliminary results
exist indicating that this noninvasive technique may be a
potential tool for therapy monitoring and for evaluating the
eﬀectiveness of modern tumour treatment.
New PET radiopharmaceutical tracers such as 3-ﬂouro-
3-deoxy-L-thymidine (18F-FLT) which is taken up into cells
in relation to the rate of DNA synthesis are being studied
[44]. They may visualise the higher cycling activity of
haemopoeitic cells in the bone marrow compartment and
may be helpful in distinguishing separate haematological
disorders.
7. Conclusion
It is clear that no one radiological technique in isolation
is perfect in accurately staging and monitoring patients
with multiple myeloma, and that there are nuances and
pitfalls associated with even the most advanced techniques.
Whole-body MR, CT, and PET/CT can provide valuable
complimentaryinformationwhenusedinthecorrectsetting.
As the availability of these techniques increase, so too
will their use. This is becoming increasingly important
as clinicians strive to best assess the appropriateness and
eﬀectiveness of new and changing treatment regimes. Newer
and more sensitive imaging techniques, including CT and
MR whole-body imaging and functional imaging modalities
including PET/CT and 99Technitium-2-methoxy-isobutyl-
isonitrile open up new avenues in assessing not only mor-
phologicaldiseaseactivity,butalsofunctionaldiseaseactivity
whichmaybeofuseinassessingresponsetotreatmentaswell
as tailoring treatment modalities to individual patients.
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